Hagyeong Kim

1 INTRODUCTION Chinese hamster ovary (CHO) cells stand out as the most predominant host cell line in biopharmaceutical production, with 95 out of 107 FDA-approved biopharmaceuticals being manufactured in these cells.[1] The noteworthy advantages of CHO cells include the ease of scaling-up, robust growth in chemically defined serum-free medium, and the ability to synthesize proteins with glycosylation patterns similar to those of humans.[2] Although a tremendous increase in volumetric...